Cort
Phoenix Rising Founder
- Messages
- 7,392
Markers of non-coeliac wheat sensitivity in patients with myalgic encephalomyelitis/chronic fatigue syndrome.Melanie Uhde1,2,Alyssa C Indart1, Xuechen B Yu1,3, Sophie S Jang1,3, Roberto De Giorgio4, Peter H R Green1,2, Umberto Volta4,Suzanne D Vernon5, Armin Alaedini1,2,3
http://gut.bmj.com/content/early/2018/03/17/gutjnl-2018-316133
This published "letter" reported on celiac disease and gluten sensitivity in about 130 ME/CFS patients. It found increased rates of gluten sensitivity in ME/CFS but not celiac disease. The rates of gluten sensitivity (GS) were not that high (15%) but enough for anyone who has gut symptoms - gut symptoms were correlated with GS in this study - to consider removing gluten products from their diet and seeing what happens.
Accordingly, the algorithm identified one (0.76%) patient with ME/CFS and two (2.3%) control subjects as belonging to the coeliac disease group (P=0.3). In contrast, 20 (15.3%) patients with ME/CFS and 4 (4.6%) control subjects were categorised in the NCWS group (P=0.015). There was also a significant correlation between the calculated NCWS probability and the GI symptom severity total score in patients with ME/CFS (r=0.231, P=0.011).
Our results suggest that there may be a subset of patients with ME/CFS who have sensitivity to wheat and related cereals in the absence of coeliac disease, with potential relevance to some of their symptoms. ME/CFS is recognised as a condition with a spectrum of clinical phenotypes and underlying aetiologies. Characterisation of patients into subsets based on clinical and biological data is essential to gaining a better understanding of the condition and identifying useful biomarkers and therapeutic targets. The results of this analysis provide a rationale for examining the clinical and therapeutic relevance of food sensitivity, particularly NCWS, in the context of ME/CFS in future studies.
http://gut.bmj.com/content/early/2018/03/17/gutjnl-2018-316133
This published "letter" reported on celiac disease and gluten sensitivity in about 130 ME/CFS patients. It found increased rates of gluten sensitivity in ME/CFS but not celiac disease. The rates of gluten sensitivity (GS) were not that high (15%) but enough for anyone who has gut symptoms - gut symptoms were correlated with GS in this study - to consider removing gluten products from their diet and seeing what happens.
Accordingly, the algorithm identified one (0.76%) patient with ME/CFS and two (2.3%) control subjects as belonging to the coeliac disease group (P=0.3). In contrast, 20 (15.3%) patients with ME/CFS and 4 (4.6%) control subjects were categorised in the NCWS group (P=0.015). There was also a significant correlation between the calculated NCWS probability and the GI symptom severity total score in patients with ME/CFS (r=0.231, P=0.011).
Our results suggest that there may be a subset of patients with ME/CFS who have sensitivity to wheat and related cereals in the absence of coeliac disease, with potential relevance to some of their symptoms. ME/CFS is recognised as a condition with a spectrum of clinical phenotypes and underlying aetiologies. Characterisation of patients into subsets based on clinical and biological data is essential to gaining a better understanding of the condition and identifying useful biomarkers and therapeutic targets. The results of this analysis provide a rationale for examining the clinical and therapeutic relevance of food sensitivity, particularly NCWS, in the context of ME/CFS in future studies.